IWM
RARE icon

IHT Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

IHT Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10
Closed – – 1743
2017
Q4 		$0 Hold
10
– – ﹤0.01% 1760
2017
Q3 		$1K Buy
+10
New +$593 ﹤0.01% 1342

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

IHT Wealth Management's RARE Position: Q1 2018 in Review

IHT Wealth Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2018, closing a stake of 10 shares.

IHT Wealth Management first reported a position in RARE in Q3 2017 and held it in 2 quarters. The position peaked at $1K in Q3 2017. 165 funds tracked by Wall St. Rank hold RARE as of Q1 2018.

  • IHT Wealth Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2018 after selling out during the quarter.
  • IHT Wealth Management sold 10 Ultragenyx Pharmaceutical shares in Q1 2018.
  • IHT Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q3 2017 and held it in 2 quarters.
  • IHT Wealth Management's Ultragenyx Pharmaceutical position peaked at $1K in Q3 2017.
  • 165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2018.

Based on IHT Wealth Management's 13F filing for Q1 2018, filed 15 May 2018.